Alaunos Therapeutics

TCRT

Market cap $5.01M

TCRT Hedge Fund Activity: Q1 2026 in Review

29 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q1 2026, worth a combined $361K — up 3% from $350K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new TCRT positions and 1 closed out — a net gain of 5 holders — while 6 added to existing stakes and 4 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $31.5K. The largest seller was Two Sigma Investments, cutting an estimated $23.2K.

• 29 institutional investors held Alaunos Therapeutics (TCRT) as of Q1 2026, up from 27 in Q4 2025.
• Funds reported $361K of Alaunos Therapeutics stock for Q1 2026, up 3% quarter-over-quarter.
• 6 funds opened new Alaunos Therapeutics positions in Q1 2026 and 1 closed out, a net change of +5 holders.
• The largest Alaunos Therapeutics buyer in Q1 2026 was Citadel Advisors, an estimated $31.5K added.
• The largest Alaunos Therapeutics seller in Q1 2026 was Two Sigma Investments, an estimated $23.2K sold.

Based on aggregated 13F filings for Q1 2026.